Healio

FDA approves single-injection viscosupplement to treat knee osteoarthritis

Please provide your email address to receive an email when new articles are posted on . The FDA has granted marketing approval to Genzyme Corp. for its Synvisc-One product indicated for the relief of ...
FiercePharma

Carbylan BioSurgery Completes Enrollment in Key Clinical Feasibility Study of Hydros and Hydros TA in Patients With Pain From Kn

PALO ALTO, Calif., Jan. 5, 2011 /PRNewswire/ -- Carbylan BioSurgery, Inc. announced today the completion of patient enrollment in their double-blinded, multi-center COR1.0 feasibility trial to ...
Monthly Prescribing Reference

Synvisc-One approved for osteoarthritis knee

Synvisc-One (hylan G-F 20, from Genzyme), has been FDAapproved for the relief of pain associated with osteoarthritis (OA) of the kneein patients who have failed to respond adequately to ...
Business Wire

Fidia Introduces in the US the 3-injection regimen TRILURON™ (sodium hyaluronate)

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid-based products and its wholly owned subsidiary, Fidia ...
PharmiWeb

Viscosupplementation Market is on a trajectory to achieve a value of US$ 2.89 Billion by 2030, driven by the increasing prevalence of arthritis | FMI

There are millions of people suffering from joint discomfort in the world. It can drastically reduce movement and worsen quality of life while also creating discomfort. However, Viscosupplementation ...
Monthly Prescribing Reference

Triluron Now Available for Osteoarthritis Knee Pain

Senior woman suffering from pain in knees at home. Holding her knee and massaging with hands, feeling exhausted, sitting on sofa in living room. Close-up. Medications and pills on table Fidia Pharma ...